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Abstract
Patients newly admitted to rehabilitation centres are at high risk of colonization with multidrug-resistant bacteria because many of them
have experienced prolonged stays in other healthcare settings and have had high exposure to antibiotics. We conducted a prospective
study to determine the prevalence of and risk factors for colonization with extended-spectrum beta-lactamase-producing
Enterobacteriaceae (ESBL-PE) in this population. Subjects were screened by rectal swab for ESBL-PE within 2 days of admission.
Swabs were plated on chromagar ESBL plates and the presence of ESBL was veriﬁed by a central laboratory. A multilevel mixed effects
model was used to identify risk factors for ESBL-PE colonization. Of 2873 patients screened, 748 (26.0%) were positive for ESBL-PE. The
variables identiﬁed as independently associated with ESBL-PE colonization were: recent stay in an acute-care hospital for over 2 weeks
(OR = 1.34; 95% CI, 1.12, 1.6), history of colonization with ESBL-PE (OR = 2.97; 95% CI, 1.99, 4.43), unconsciousness on admission
(OR = 2.59; 95% CI, 1.55, 4.34), surgery or invasive procedure in the past year (OR = 1.49; 95% CI, 1.2, 1.86) and antibiotic treatment
in the past month (OR = 1.80; 95% CI, 1.45, 2.22). The predictive accuracy of the model was low (area under the ROC curve 0.656).
These results indicate that ESBL-PE colonization is common upon admission to rehabilitation centres. Some risk factors for ESBL-PE
colonization are similar to those described previously; however, newly identiﬁed factors may be speciﬁc to rehabilitation populations.
The high prevalence and low ability to stratify by risk factors may guide infection control and empirical treatment strategies in
rehabilitation settings.
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Introduction
Over the past 10 years, there has been an increasing incidence
of serious infections with antimicrobial-resistant Gram-nega-
tive bacilli [1]. One of the most common mechanisms of
resistance is the production of beta-lactamases, which are
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hydrolytic enzymes with the ability to inactivate the beta-
lactam class of antibiotics [2]. The presence of extended-
spectrum beta-lactamases (ESBL) in various members of the
Enterobacteriaceae family, particularly Klebsiella pneumoniae
and Escherichia coli, is of great microbiological and clinical
importance [2].
While data regarding colonization with ESBL-producing
Enterobacteriaceae (ESBL-PE) in acute-care hospitals are
widely available [1,2], ﬁrm data regarding long-term care
facilities (LTCFs) such as rehabilitation centres are lacking.
However, the magnitude of care given in those facilities has
dramatically increased in the last decade, leaving the question
of ESBL-PE prevalence important but unanswered.
Among LTCFs, rehabilitation centres constitute a hetero-
geneous group of institutions that provide care to a large
number of patients with different needs. Patients in rehabil-
itation centres are at high risk of colonization and potential
infection with multidrug-resistant bacteria because a majority
of them have been in other healthcare settings for an extended
period of time and have had high exposure to antibiotics [3,4].
Moreover, host-related factors that are common among the
rehabilitation centre population, such as older age, poor
functional status, mental impairment, alterations in mobility or
swallowing and urinary incontinence, are especially associated
with higher risk of developing infections [3,4]. Another
problem is the frequent patient exchange between rehabilita-
tion centres and acute-care hospitals, which might place
patients in both settings in danger [3,4]. This patient exchange
deserves special attention when designing infection control
strategies.
Prior studies have provided a wide range of estimates of the
prevalence of colonization or infection with ESBL-PE in
long-term care facilities, between 3.4% and 64% [4–7];
however, most of these studies assessed ESBL-PE prevalence
using clinical isolates [4,6,7], while only a few used active
surveillance [5,8]. Moreover, most of these studies took place
in long-term care facilities such as nursing homes or veterans
centres and not in rehabilitation centres [4–8], and most were
single-centre point prevalence studies on residents with
various lengths of stay [4–8].
The Mastering Hospital Antimicrobial Resistance in Europe
(MOSAR) team has published on the molecular epidemiology
of ESBL, the spread to family members and healthcare
workers, and the dynamic of patient to patient spread of ESBL
within rehabilitation centres [9–11]. The aim of the present
study was to expand our analyses in order to determine in a
large sample, the prevalence of and risk factors for ESBL-PE
colonization on admission to rehabilitation centres in four
countries.
Methods
Setting
The study was conducted in eight wards in ﬁve rehabilitation
centres in Tel-Aviv (Israel), Ra’anana (Israel), Barcelona (Spain),
Rome (Italy) and Berck (France). The total number of hospital
beds in these wards is 335; 203 are for neurological rehabili-
tation, 79 for orthopedic rehabilitation and one ward of 53 beds
is dedicated to both. The study population was comprised of all
adult patients who were newly admitted to each centre in the
study period, as follows: October 2008 to December 2010 (Tel
Aviv), May 2009 to March 2011(Ra’anana), February 2009 to
February 2011 (Barcelona and Rome) and June 2009 to March
2011 (Berck). Patients were included in this analysis if a
screening culture for ESBL-PE was performed within 2 days of
admission. Rectal swabs were taken by the facility staff, primarily
during the morning shift. All staff were trained on how to get
quality swabs by the research team.
Design
This was a prospective study performed as part of the MOSAR
project. MOSAR is a transdisciplinary, multinational network
devoted to combating and controlling antimicrobial resistance
among bacteria responsible for major and emerging nosoco-
mial infections that also spread into the community.
Data collection
The following data were recorded: demographic characteris-
tics (age and sex); co-morbidities, which were used to calculate
the Charlson score [12]; hospitalization or LTCF stay in the
past 6 months; history of colonization or infection with
ESBL-PE or other multidrug-resistant organisms (methicil-
lin-resistant S. aureus, vancomycin-resistant enterococcus or
Acinetobacter baumannii); level of consciousness on admission;
presence of quadriplegia or immunosuppression; history of
surgery or invasive procedures in the past year; and history of
invasive devices or antibiotic treatment in the past month.
Microbiological methods
Specimen handling and isolate identiﬁcation were performed
using a standard protocol. Screening for colonization with
ESBL-PE was performed by rectal swab. The swabs were
transferred immediately to the microbiology laboratory and
streaked onto Brilliance ESBL agar (Oxoid, Basingstoke, UK).
The Brilliance ESBL agar was chosen due to its proven high
sensitivity (95%) and high negative predictive value (99.3%) in
identiﬁcation or exclusion of patients carrying ESBL-PE [13].
Growing colonies were considered presumptive ESBL-PE
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based on morphology and colour, as previously described and
validated [14]. Colonies were identiﬁed according to the
manufacturer’s instructions as follows: dark blue/violet or pink,
Escherichia coli; turquoise/green, Klebsiella/Enterobacter/Serratia/
Citrobacter spp.; tan/light brown, Proteus/Providencia/Morganella
spp. These tests were supplemented by oxidase tests when
necessary to exclude Pseudomonas. All isolates classiﬁed as
presumptive ESBL-PE were stored at 70°C and transferred
to one of two central laboratories at Antwerp, Belgium or
Warsaw, Poland, for further testing. Transfer was arranged via
certiﬁed courier every 6–12 months as required. In the central
laboratories, isolates were further identiﬁed by conventional
and semiautomatic (API20NE/E, BioMerieux, Marcy L’Etoile,
France) biochemical testing. The phenotypic detection of ESBL
and AmpC expression was carried out using the ESBL
double-disk synergy test with disks containing cefotaxime,
ceftazidime, cefepime and amoxicillin with clavulanate on
Mueller-Hinton agar (Oxoid) non-supplemented and supple-
mented with 250 mg/mL cloxacillin [15]. An isolate was
considered ESBL-positive only if conﬁrmed by one of the
central laboratories.
Statistical analysis
Risk factors were analysed by comparing ESBL-PE colonized and
non-colonized patients. Univariate analysis was performed using
Student’s t-test for continuous variables and the Pearson v2 test
for categorical variables. All variables with a p-value <0.1 were
considered for the multivariable logistic regression model. The
ﬁnal model was chosen using forward stepwise selection. We
used a multilevel mixed effects model with study site as the
ﬁrst-level random effects variable. The area under the ROC
curve was calculated to assess the predictive accuracy of the
model. To isolate the effect of a single antibiotic/antibiotic class,
we used Fisher’s exact test to compare patients who received a
drug class as monotherapy (i.e. not in combination with other
antibiotics) with patients who received no antibiotics. We
analysed only antibiotics that had been given as monotherapy to
at least ﬁve ESBL-PE colonized and non-colonized patients.
Finally, multilevel mixed effects models were constructed to
determine risk factors for colonization with ESBL-producing
E. coli and ESBL-producing K. pneumoniae; for these models,
colonized patients with the organism of interest were com-
pared with all other subjects (i.e. those negative for ESBL-PE and
those who were found to be colonized with other species of
ESBL-PE). Data were analysed using Stata version 12.1(Stata-
Corp, College Station, TX, USA).
Ethics
The study was approved by each centre’s institutional review
board.
Results
A total of 2873 patients were screened for ESBL-PE rectal
colonization on admission to the rehabilitation centre. The
patients’ mean age was 66 years; 49% were male, and 86%
were admitted from an acute-care facility. Seven hundred and
forty-eight patients (26.0%) tested positive for ESBL-PE. The
prevalence of ESBL-PE colonization on admission in the
different rehabilitation centres was as follows: 18.6% in Berck,
21.1% in Ra’anana, 21.5% in Rome, 30.6% in Tel Aviv and 36.9%
in Barcelona.
Table 1 shows the background characteristics and co-mor-
bidities of study subjects according to ESBL-PE colonization
status. In multivariable analysis, independent predictors of
colonization with ESBL-PE were a recent acute-care hospital
stay longer than 2 weeks, history of ESBL-PE colonization,
unconsciousness on admission to the rehabilitation centre,
history of surgery/invasive procedure in the past year, and
antibiotic treatment in the past month (Table 2, Model 1). The
model had poor predictive accuracy (area under the ROC
curve, 0.656). Fig. 1 presents this same model for each study
site. There was a signiﬁcant interaction between study site and
antibiotic treatment (p 0.042); the effect of the other four
variables was similar across settings.
Among 1563 patients who received antibiotics in the last
month, 785 were treated with monotherapy (592 cephalo-
sporins, 93 ﬂuoroquinolones, 22 penicillins + beta-lactamase
inhibitor, 19 aminoglycosides, 13 carbapenems, 12 penicillins,
11 vancomycin, 11 other glycopeptides, 6 macrolides, 4
metronidazole and 2 tetracyclines) and 375 with combination
therapy, and in 403 cases, the antibiotic treatment could not
be determined from the medical records. In univariate
analysis that compared patients who received an antibiotic/
antibiotic class as monotherapy with patients who received
no antibiotics, ESBL-PE colonization was signiﬁcantly
associated with the use of cephalosporins (OR = 2.15; 95%
CI, 1.72, 2.69), penicillins (OR = 6.27; 95% CI, 1.97, 19.94)
or vancomycin (OR = 3.73; 95% CI, 1.13, 12.34). There was
no signiﬁcant association between colonization with ESBL-PE
and recent use of aminoglycosides, ﬂuoroquinolones or
beta-lactams/beta-lactamase inhibitors. Table 2, Model 2,
presents the multivariable models in which we substituted
monotherapy with cephalosporins and monotherapy with
penicillins for ‘any antibiotic treatment.’ These substitutions
only minimally improved the predictive accuracy of the
model (area under the ROC curve, 0.660 for Model 2 and
0.670 for Model 3). In multivariable analysis, vancomycin
monotherapy was no longer a signiﬁcant predictor of
ESBL-PE carriage.
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The prevalence of colonization with ESBL-producing E. coli
and ESBL-producing K. pneumonia, respectively, in the different
study sites was as follows: 7.7% and 6.1% in Berck, 10.0% and
5.9% in Rome, 18.2% and 11.8% in Barcelona, 8.4% and 3.2% in
Ra’anana and 15.2% and 8.4% in Tel Aviv. In a multilevel mixed
effects model, the variables signiﬁcantly associated with
ESBL-producing E. coli colonization were acute-care hospital
stay longer than 2 weeks in the past 6 months (OR = 1.33;
95% CI, 1.05, 1.68; p 0.017), history of colonization with
ESBL-PE (OR = 2.08; 95% CI, 1.28, 3.39; p 0.003) and
antibiotic treatment in the past month (OR = 1.49; 95%
CI, 1.15, 1.94; p 0.003) (area under the ROC curve, 0.623).
The variables signiﬁcantly associated with ESBL-producing
K. pneumoniae colonization were acute-care hospital stay
longer than 2 weeks in the past 6 months (OR = 1.53; 95%
CI, 1.12, 2.09; p 0.008), history of colonization with ESBL-PE
(OR = 4.27; 95% CI, 2.58, 7.08; p 0.000), antibiotic treatment
in the past month (OR = 2.06; 95% CI, 1.41, 3.01; p 0.000) and
surgery or invasive procedure in the past year (OR = 1.86;
95% CI, 1.24, 2.78; p 0.003) (area under the ROC curve,
0.693).
Discussion
In this large multicentre study we prospectively studied the
prevalence of and risk factors for ESBL-PE colonization on
admission to rehabilitation centres. Our main ﬁnding is that
colonization with ESBL-PE is highly prevalent on admission to
all rehabilitation centres studied, averaging 26%.
While the prevalence of ESBL-producing organisms in
clinical isolates taken from LTCF residents has been reported
to be as high as 25.6–55.3% [4,6,7], ESBL-PE colonization in
these settings is reported to range between 3.4 and 64% [5,8].
Lautenbach et al. found the prevalence of ESBL-producing
E. coli and Klebsiella spp. colonization among 239 residents of
three LTCFs in the US to be only 3.4%, with prevalence
differing signiﬁcantly across the three study sites (0.8–10.7%).
TABLE 1. Factors associated with ESBL-PE colonization on admission to rehabilitation centres; univariate analysis
ESBL-PE colonization
(n = 748)
ESBL-PE non-colonization
(n = 2125) OR (95% CI) p value
Male sex, n (%) 369 (49.3) 1035 (48.7) 0.98 (0.83, 1.15) 0.77
Age, mean (SD) 68.0 (20.1) 66.1 (19.4) 1.00 (1.00, 1.01) 0.025
Admitted from acute-care facility, n (%) 688 (92.0) 1804 (84.9) 2.04 (1.53, 2.72) <0.001
Long (>2 weeks) acute-care hospital stay
in past 6 months, n (%)
416 (56.1) 1008 (47.7) 1.40 (1.18, 1.66) <0.001
Stay in another long-term care facility in
past 6 months, n (%)
142 (20.1) 423 (20.5) 0.98 (0.79, 1.21) 0.84
History of colonization with ESBL-PE, n (%) 59 (7.9) 73 (3.4) 2.41 (1.69, 3.43) <0.001
History of colonization with multidrug-
resistant bacteria other than ESBL-PE, n (%)
47 (6.3) 91 (4.3) 1.50 (1.04, 2.15) 0.028
Unconscious on admission, n (%) 33 (4.4) 38 (1.8) 2.53 (1.58, 4.07) <0.001
Charlson score, mean (SD) 1.28 (1.61) 1.28 (1.63) 1.00 (0.95, 1.05) 0.99
Tetraplegia/quadriplegia, n (%) 99 (13.2) 241 (11.3) 1.19 (0.93, 1.53) 0.17
Immunosuppressed, n (%) 40 (5.4) 82 (3.9) 1.41 (0.96, 2.07) 0.084
Surgery/invasive procedure in
the past year, n (%)
576 (77.0) 1342 (63.2) 1.95 (1.61, 2.37) <0.001
Invasive device in the past month, n (%) 608 (81.4) 1453 (68.5) 2.01 (1.64, 2.47) <0.001
Antibiotic treatment in the past month, n (%) 509 (68.1) 1054 (49.6) 2.16 (1.81, 2.58) <0.001
Study site
Berck 70 (18.6%) 307 (81.4%) Reference <0.001
Ra’anana 93 (21.1%) 348 (78.9%) 1.17 (0.83, 1.66)
Rome 131 (21.5%) 478 (78.5%) 1.20 (0.87, 1.66)
Tel-Aviv 385 (30.6%) 874 (69.4%) 1.93 (1.45, 2.57)
Barcelona 69 (36.9%) 118 (63.1%) 2.56 (1.73, 3.80)
TABLE 2. Factors associated with ESBL-PE colonization on admission to rehabilitation centres; multivariable analysis
Model 1 Model 2
OR (95% CI) p-value OR (95% CI) p-value
Long (>2 weeks) acute-care hospital stay
in past 6 months
1.34 (1.12, 1.60) 0.002 1.29 (1.02, 1.62) 0.032
History of colonization with ESBL-PE 2.97 (1.99, 4.43) <0.001 3.22 (2.01, 5.16) <0.001
Unconscious on admission 2.59 (1.55, 4.34) <0.001 2.58 (1.44, 4.63) <0.001
Surgery/invasive procedure in the past year 1.49 (1.20, 1.86) <0.001 1.60 (1.22, 2.09) <0.001
Any antibiotic treatment in the past montha 1.80 (1.45, 2.22) <0.001 – –
Cephalosporin monotherapy in the past montha – – 1.69 (1.22, 2.35) 0.002
Penicillin monotherapy in the past montha – – 4.91 (1.46, 16.50) 0.010
aCompared with patients who received no antibiotics.
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However, it was almost impossible to derive risk factors for
colonization because of the small sample size (only eight
positive isolates) [5]. March et al. [8] conducted a point
prevalence study in an LTCF and geriatric units in an
acute-care hospital in Italy and found 64% and 8.9% positive
ESBL-PE cultures in these two settings, respectively. The LTCF
they studied was not a rehabilitation centre and was
comprised primarily of elderly residents [8].
When reviewing the ﬁndings of studies of the prevalence of
colonization in LTCFs, two critical points should be consid-
ered. First, at what point during the LTCF stay was coloni-
zation assessed? If, as in our study, the researchers examined
colonization on admission, then the results represent the
imported burden of ESBL-PE into the LTCF; if the study is a
point prevalence study of all residents, then there is a mixture
of imported cases and those acquired during the LTCF stay.
Second, does the study evaluate colonization, clinical infection
(which occurs in only a fraction of colonized patients), or both?
The European Antimicrobial Resistance Surveillance Net-
work (EARS-NET) reports (which do not include Israeli data)
show a dramatic increase from 2007 to 2010 in the percentage
of E. coli isolates resistant to third-generation cephalosporins.
This rise has been linked primarily to the spread of ESBL-pro-
ducing organisms [16]. According to EARS-NET, in 2010 the
proportion of invasive E. coli isolates that were resistant to
third-generation cephalosporins was 7% in France, 12% in
Spain and 21% in Italy. In comparison, in our study the
proportion of E. coli rectal isolates that were ESBL-positive
was 7% in France, 18% in Spain and 10% in Italy. Likewise, in
EARS-NET the proportion of K. pneumoniae blood isolates
that were resistant to third-generation cephalosporins was
18% in France, 10% in Spain and 47% in Italy; in our study, the
FIG. 1. Factors associated with ESBL-PE colonization on admission to rehabilitation centres; multivariable analysis by study site. Square/
triangle = odds ratio, whiskers = 95% conﬁdence interval. *Barcelona and Ra’anana omitted because <4 subjects were unconscious on
admission.
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proportion of K. pneumoniae rectal isolates that were
ESBL-positive was 6% in France and Italy and 12% in Spain.
However, one should bear in mind that direct comparison of
our data with the EARS-NET data might be imperfect, due to
the fact that the latter shows the fraction of antibiotic
resistance strains among invasive isolated strains. Other
potential explanations for the differences between our ﬁndings
and the EARS-NET data are regional differences in the
prevalence of resistant organisms (our data come from one
institution in each country while EARS-NET data are coun-
try-wide), or differences between the LTCF residents in our
study and the acute-care hospital patients represented in
EARS-NET.
Our report on the extremely high colonization rate on
admission to rehabilitation centres is alarming: one in every
four patients admitted was colonized with ESBL-PE. As LTCF
stays are often long, and transfer of patients between
rehabilitation centres and acute-care hospitals is common,
these colonized patients may be a source of transmission in
both settings. We recently demonstrated signiﬁcant transmis-
sion of ESBL-producing E. coli in LTCFs with clonal and gene
variability [9]. These data should be taken into account when
designing infection control strategies in LTCFs as well as in
acute-care hospitals.
Our large study allowed us to identify several risk factors
for colonization. Moreover, it allowed separate analysis of risk
factors for ESBL-producing E. coli and for ESBL-producing
Klebsiella pneumoniae. Direct comparison with previous studies
is limited due to differences in study design and study
populations. One risk factor, recent antibiotic treatment,
was identiﬁed both in our study and in the study by March
et al. [8] in Italian LTCFs. March identiﬁed two other risk
factors for ESBL-PE colonization in LTCFs: age ≥86 (not
signiﬁcant in our study) and physical disability (not measured in
our study). While our study identiﬁed unconsciousness on
admission as an independent risk factor, this variable is
collinear with physical disability and poor functional status,
and thus may represent the same group of factors leading to
colonization. We also found that a long stay in an acute-care
hospital in the past 6 months, surgery in the past year and a
history of colonization with ESBL-PE were signiﬁcantly asso-
ciated with ESBL-PE colonization on admission. While transfer
from LTCFs has long been recognized as a risk factor for
ESBL-PE on admission to acute-care hospitals, our ﬁndings
suggest that the reverse is also true: as the vast majority of our
LTCF patients were transferred from acute care, many of
these patients are likely to have acquired the organisms during
their acute-care stay. Interestingly, but not surprisingly, there
is some overlap between risk factors found in this study,
including recent stay in acute-care hospital, and risk factors we
identiﬁed in our previous report regarding carriage of
methicillin-resistant Staphylococcus aureus on admission to
LTCF [17].
We examined risk factors for colonization with ESBL-pro-
ducing E. coli and for ESBL-producing K. pneumoniae. Interest-
ingly, the two models were very similar, with the exception
that surgery/invasive procedure in the past year was a risk
factor for K. pneumoniae but not for E. coli.
All the models poorly predicted ESBL-PE status, with area
under the ROC curves of <0.7. The poor prediction
together with the high prevalence found implies that
stratiﬁcation by risk factors will miss many colonized patients
with ESBL-PE; therefore other methods are required for
decision making in this setting, regarding both empirical
therapy and infection control strategies. Some of these
methods can be screening based; alternatively, it may be
sensible to apply a uniform strategy that assumes that all
patients are ESBL-PE positive.
Our study points to the high prevalence of ESBL-PE
colonization on admission to rehabilitation centres in various
countries, the similarity of risk factors between centres, and
the poor ability to predict ESBL-PE colonization in these
patients based on risk factors. Strategies to limit the spread of
ESBL-PE in LTCFs and acute-care hospitals should be designed
taking these ﬁndings into account.
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